Insulin secretagogues: Who, what, when, and how?

Current Diabetes Reports

Volumn 5, Issue 5, 2005, Pages 329-332

  Dailey, George ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETOHEXAMIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; INSULIN SENSITIZING AGENT; MEGLITINIDE; MEGLITINIDE DERIVATIVE; METFORMIN; NATEGLINIDE; PHENFORMIN; REPAGLINIDE; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; UNCLASSIFIED DRUG; WARFARIN;

BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DOSE RESPONSE; FLUSHING; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; REVIEW; RISK ASSESSMENT; WEIGHT GAIN;

EID: 27744599352     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-005-0089-x     Document Type: Review

References (22)

1. Henquin J: The fiftieth anniversary of hypoglycemic sulphonamides. How did the mother compound work? Diabetologia 1992, 35:907-912.
2. Dornhorst A: Insulinotropic meglitinide analogues. Lancet 2001, 358:1709-1716.
3. Carroll MF, Gutierrez A, Castro M, et al.: Targeting postprandial hyperglycemia: a comparitive study of insulinotropic agents in type 2 diabetes. J Clin Endocrinol Metab 2003, 88:5248-5254.
4. Esposito K, Guigliano D, Nappo F, Marfella R: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004, 110:214-219
5. Simonson DC, Kourides I, Feinglos M, Fischette C: Efficacy, safety, and dose-response of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Diabetes Care 1997, 20:597-606.
6. Stenman S, Melander A, Groop PH, Groop L: What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993, 118:169-173.
7. Riddle M: Combining sulfonylureas and other oral agents. Am J Med 2000, 108:15S-22S.
8. Fonseca V, Rosenstock J, Patwardhan R, et al.: Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: randomized controlled trial. JAMA 2000, 283:1695-1702.
9. Rendell M: The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004, 64:1339-1358.
10. American Association of Clinical Endocrinologists and American College of Endocrinology: American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE System of Intensive Diabetes Self-Management - 2002 Update.Endocr Pract 2002, 8(suppl 1):41-82.
11. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1999 [no authors listed]. Diabet Med 1999, 16:716-730.
12. Garber AJ, Bruce S, Fiedorek F: Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study. Clin Ther 2002, 24:1401-1413.
13. Bell DSH: Practical considerations and guidelines for dosing sulfonylurea as monotherapy or combination therapy. Clin Ther 2004, 20:1714-1727.
14. Dailey G: Early insulin: an important therapeutic strategy. Diabetes Care 2005, 28:220-221.
15. WorkGroup on Hypoglycemia, American Diabetes Association: Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005, 28:1245-1249.
16. Holstein A, Plaschke A, Egberts EH: Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001, 17:467-473.
17. Meinert CL, Knatterud GL, Prout TE, Klimt CR: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes II. Diabetes 1970, 19(suppl 2):789-830.
18. Lee TM, Chou TF: Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003, 88:531-537.
19. Danchin N, Charpentier C, Ledru F, et al.: Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev 2005, 21:143-149.
20. Wright A, Burden AC, Paisey RB, et al.: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002, 25:330-336.
21. Riddle MC: Timely addition of insulin to oral therapy for type 2 diabetes. Diabetes Care 2002, 25:395-396.
22. Fach EM, Busch K, Karimi Z, et al.: Efficacy of insulin glargine in type 2 diabetes: effect at different stages of the disease [abstract]. Diabetes 2004, 53(suppl 2):524-P.